Literature DB >> 11697909

Chaperonin-mediated de novo generation of prion protein aggregates.

J Stöckel1, F U Hartl.   

Abstract

The infectious prion protein, PrP(Sc), a predominantly beta-sheet aggregate, is derived from PrP(C), the largely alpha-helical cellular isoform of PrP. Conformational conversion of PrP(C) into PrP(Sc) has been suggested to involve a chaperone-like factor. Here we report that the bacterial chaperonin GroEL, a close homolog of eukaryotic Hsp60, can catalyze the aggregation of chemically denatured and of folded, recombinant PrP in a model reaction in vitro. Aggregates form upon ATP-dependent release of PrP from chaperonin and have certain properties of PrP(Sc), including a high beta-sheet content, the ability to bind the dye Congo red, detergent-insolubility and increased protease-resistance. A conserved sequence segment of PrP (residues 90-121), critical for PrP(Sc) generation in vivo, is also required for chaperonin-mediated aggregate formation in vitro. Initial binding of refolded, alpha-helical PrP to chaperonin is mediated by the unstructured N-terminal segment of PrP (residues 23-121) and is followed by a rearrangement of the globular PrP core-domain. These results show that chaperonins of the Hsp60 class can, in principle, mediate PrP aggregation de novo, i.e. independently of a pre-existent PrP(Sc) template. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11697909     DOI: 10.1006/jmbi.2001.5085

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  11 in total

1.  Designing a high throughput refolding array using a combination of the GroEL chaperonin and osmolytes.

Authors:  Paul A Voziyan; Mary Johnston; Angela Chao; Greg Bomhoff; Mark T Fisher
Journal:  J Struct Funct Genomics       Date:  2005

2.  Interaction of prion protein with small highly structured RNAs: detection and characterization of PrP-oligomers.

Authors:  Sara Vasan; Phyllus Y Mong; Abraham Grossman
Journal:  Neurochem Res       Date:  2006-06-02       Impact factor: 3.996

3.  Conformational stability of PrP amyloid fibrils controls their smallest possible fragment size.

Authors:  Ying Sun; Natallia Makarava; Cheng-I Lee; Pongpan Laksanalamai; Frank T Robb; Ilia V Baskakov
Journal:  J Mol Biol       Date:  2008-01-03       Impact factor: 5.469

4.  Irreversible aggregation of protein synthesis machinery after focal brain ischemia.

Authors:  F Zhang; C L Liu; B R Hu
Journal:  J Neurochem       Date:  2006-07       Impact factor: 5.372

5.  Conservation of a glycine-rich region in the prion protein is required for uptake of prion infectivity.

Authors:  Christopher F Harrison; Victoria A Lawson; Bradley M Coleman; Yong-Sun Kim; Colin L Masters; Roberto Cappai; Kevin J Barnham; Andrew F Hill
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

6.  Absence of evidence for the participation of the macrophage cellular prion protein in infection with Brucella suis.

Authors:  Pascaline Fontes; Maria-Teresa Alvarez-Martinez; Antoine Gross; Claude Carnaud; Stephan Köhler; Jean-Pierre Liautard
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  Co-translational protein aggregation after transient cerebral ischemia.

Authors:  C L Liu; P Ge; F Zhang; B R Hu
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 8.  Prions: protein only or something more? Overview of potential prion cofactors.

Authors:  Carlo Fasano; Vincenza Campana; Chiara Zurzolo
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

9.  Amyloid oligomer conformation in a group of natively folded proteins.

Authors:  Yuji Yoshiike; Ryoichi Minai; Yo Matsuo; Yun-Ru Chen; Tetsuya Kimura; Akihiko Takashima
Journal:  PLoS One       Date:  2008-09-18       Impact factor: 3.240

10.  Cellular prion protein promotes Brucella infection into macrophages.

Authors:  Masahisa Watarai; Suk Kim; Janchivdorj Erdenebaatar; Sou-ichi Makino; Motohiro Horiuchi; Toshikazu Shirahata; Suehiro Sakaguchi; Shigeru Katamine
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.